Our Phone — +7 (495) 710-68-44

Projects and activities


Longevica Pharmaceuticals

Longevica Pharmaceuticals is a biotech start-up established in 2008 by Dr. Alexey Ryazanov and focused on developing novel chemical inhibitors of eukaryotic elongation factor 2 kinase (eEF2K), a highly promising drug target whose inhibition can achieve multiple beneficial effects ranging from suppressing tumor growth to protecting normal cells from the cytotoxicity of chemotherapeutic agents. 

Rostock Group owns 51% of Longevica Pharmaceuticals. In 2014, Rostock Group initiated negotiations with pharmaceutical companies and venture capital to create drugs based on eEF2-kinase.

A study by Alexey Ryazanov "Germline Quality Control: eEF2K Stands Guard to Eliminate Defective Oocytes" published in the Development Cell Journal 

© 2009 “Rostock Group”
8/3, Pokryshkina str, Moscow, Russian Federation


Tel./Fax: +7 (495) 710-68-44
E-mail: info@grostock.ru
Web Production: 25 Кadr Advertising Agency